Spectral Medical Q1 Loss Widens, Says Tigris Trial Enrollment Reaches 106 Patients

Spectral Medical (EDT.TO) said its first quarter loss significantly widened due to higher operating expense. The company, which is developing therapies to treat sepsis, recorded a loss of $4.2 million

MT NewswiresMay 13 09:09 ET

Spectral Medical Brief: Loss for the Three-months Ended March 31, 2024 Was $4,160,000 ($0.01 per Share)

07:34 AM EDT, 05/13/2024 (MT Newswires) -- Spectral Medical Brief: Loss for the three-months ended March 31, 2024 was $4,160,000 ($0.01 per share)

MT NewswiresMay 13 07:34 ET

Spectral Medical Chair to Retire From the Board of Directors

Stockhouse Apr 2 08:00 ET

Spectral Medical Brief: Says Total of 97 Patients Randomized to Date Out of the 150 Total Patients to Be Enrolled in the Tigris Trial

04:27 PM EDT, 03/28/2024 (MT Newswires) -- Spectral Medical Brief: Says Total of 97 patients randomized to date out of the 150 total patients to be enrolled in the Tigris trial

MT NewswiresMar 28 16:27 ET

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Stockhouse Mar 28 16:00 ET

Spectral Medical Provides February Tigris Trial Update

Stockhouse Feb 28 07:30 ET